Drug-induced Liver Injury: Development of a MILLIPLEX® Map Multiplexed Assay Panel for Emerging Biomarkers

Drug-induced liver injury (DILI) is the primary adverse event that results in withdrawal of drugs from market. The liver is a multifunctional organ. As drugs may cause liver injury through various mechanisms, measurement of multiple biomarkers is required to ensure that the potential for hepatotoxicity is identified early in drug development. This application note describes a Luminex® bead-based multiplex immunoassay that can simultaneously measure PSTC-investigated hepatotoxicity biomarkers, liver-type arginase 1 (ARG1), α-glutathione-S-transferase (GST-α), 5’nucleotidase (5NT) and sorbitol dehydrogenase (SDH), as well as the recently discovered biomarker, glutamic-oxaloacetic transaminase 1 (GOT1), in the blood.